Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -33,887 | -38,243 | -48,818 | -33,017 | -24,774 |
| Depreciation Amortization | 821 | 811 | 790 | 699 | 524 |
| Other Working Capital | -704 | -932 | -3,149 | 38,167 | 1,690 |
| Other Operating Activity | 9,190 | 5,292 | 3,842 | 2,795 | 1,694 |
| Operating Cash Flow | $-24,580 | $-33,072 | $-47,335 | $8,644 | $-20,866 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -104 | -11 | -153 | -366 | -133 |
| Investing Cash Flow | $-104 | $-11 | $-153 | $-366 | $-133 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -10 | -9 | -4 | -49 | -85 |
| Common Stock Issued | N/A | 29,330 | 14,874 | 23,158 | 35,306 |
| Other Financing Activity | -207 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $-217 | $29,321 | $14,870 | $23,109 | $35,221 |
| Exchange Rate Effect | 6 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 73,228 | 76,990 | 109,608 | 78,221 | 63,999 |
| End Cash Position | 48,333 | 73,228 | 76,990 | 109,608 | 78,221 |
| Net Cash Flow | $-24,895 | $-3,762 | $-32,618 | $31,387 | $14,222 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,580 | -33,072 | -47,335 | 8,644 | -20,866 |
| Capital Expenditure | -104 | -11 | -153 | -366 | -133 |
| Free Cash Flow | -24,684 | -33,083 | -47,488 | 8,278 | -20,999 |